Skip to Content
Merck
All Photos(1)

Documents

1378001

USP

Medroxyprogesterone acetate

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

Medroxyprogesterone 17-acetate, 17α-Acetoxy-6α-methylprogesterone, 17α-Hydroxy-6α-methyl-4-pregnene-3,20-dione 17-acetate, 6α-Methyl-17α-acetoxyprogesterone, 6α-Methyl-17α-hydroxyprogesterone acetate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C24H34O4
CAS Number:
71-58-9
Molecular Weight:
386.52
Beilstein:
2066112
MDL number:
MFCD00010483
UNSPSC Code:
41116107
PubChem Substance ID:
329750335
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

medroxyprogesterone

manufacturer/tradename

USP

mp

206-207 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

[H][C@@]12C[C@H](C)C3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@@]4(C)[C@@]2([H])CC[C@]4(OC(C)=O)C(C)=O

InChI

1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1

InChI key

PSGAAPLEWMOORI-PEINSRQWSA-N

Gene Information

human ... PGR(5241)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Medroxyprogesterone acetate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Medroxyprogesterone Acetate Injectable Suspension
  • Medroxyprogesterone Acetate Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H351,H413

Hazard Classifications

Aquatic Chronic 4 - Carc. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 4

1 of 4

Minoxidil United States Pharmacopeia (USP) Reference Standard

USP

1444208

Minoxidil

Testosterone cypionate United States Pharmacopeia (USP) Reference Standard

USP

1647001

Testosterone cypionate

Docusate sodium meets USP testing specifications

Sigma-Aldrich

D1685

Docusate sodium

Ethylparaben Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1011

Ethylparaben

J Mitsushita et al.
Gynecologic oncology, 79(1), 129-132 (2000-09-28)
Successful pregnancies after conservative progestin treatment to young women with endometrial carcinoma have recently been reported. However, it is not known for certain whether the lesion is completely eradicated in such patients. We present a case of residual endometrial carcinoma
Edith R Guilbert et al.
Contraception, 79(3), 167-177 (2009-02-03)
In the fall of 2007, the controversy about the contraceptive use of depot-medroxyprogesterone acetate (DMPA) and its potential impact on skeletal health reached the media in the province of Quebec, Canada, thereby becoming a matter of concern for the lay
Andrew M Kaunitz et al.
Contraception, 77(2), 67-76 (2008-01-30)
While depot medroxyprogesterone acetate (DMPA) is a highly effective contraceptive used by millions of women, its use is associated with bone mineral density (BMD) loss, raising concerns about long-term risk of osteoporosis and/or fractures. We conducted a systematic review of
R Kent Hermsmeyer et al.
Nature clinical practice. Cardiovascular medicine, 5(7), 387-395 (2008-06-04)
Heart disease presentation can differ between the sexes because nonobstructive coronary disease and angina unrelated to exercise are considerably more prevalent in women than in men. When the outcomes of large, randomized, controlled trials failed to demonstrate cardiac risk protection
Frank Z Stanczyk et al.
The Journal of steroid biochemistry and molecular biology, 142, 30-38 (2013-12-03)
Medroxyprogesterone acetate (MPA) has been in clinical use for over 30 years, and was generally considered to be safe until the results of long-term studies of postmenopausal hormone therapy (HT) using treatment with conjugated equine estrogens (CEE) combined with MPA
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service